Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings?
by Zacks Equity Research
During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $65.23, marking a -0.18% move from the previous day.
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco Systems, SAP, Gilead Sciences, Bank of America and Caterpillar
Top Stock Reports for Cisco, SAP & Gilead
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), SAP (SAP) and Gilead Sciences (GILD).
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $63.99, moving +1.15% from the previous trading session.
Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
by Zacks Equity Research
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
Why Gilead (GILD) Could Beat Earnings Estimates Again
by Zacks Equity Research
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
by Zacks Equity Research
Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.
Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates
by Zacks Equity Research
Key highlights of the past week include label expansion of drugs, licensing deals and more.
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
by Zacks Equity Research
Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
Novo Nordisk Focuses on Pipeline Development Amid Competition
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $62.23, marking a +0.99% move from the previous day.
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
Enanta's Stock Down Despite NASH Drug Meeting Goal in Study
by Zacks Equity Research
Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $64.20, marking a -0.56% move from the previous day.
Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval
by Zacks Equity Research
Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.
Merck's Two HIV Drugs Get FDA Approval for Expanded Use
by Zacks Equity Research
Merck's (MRK) new HIV drugs, Pifeltro and Delstrigo, get FDA nod for use in treatment-experienced adults living with HIV-1 who are virologically suppressed.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $66.17, marking a +0.44% move from the previous day.